Dimerix (OTCPK:SBMJ.F) - Stock Price, News & Analysis

SBMJ.F Stock Overview

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

SBMJ.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 29.5% per year over past 5 years

Shares are highly illiquid

Makes less than USD$1m in revenue (A$583K)

Shareholders have been diluted in the past year

Dimerix Limited Competitors

Inovio Pharmaceuticals

NasdaqCM:INO

US$152.2m

MacroGenics

NasdaqGS:MGNX

US$200.1m

Tenaya Therapeutics

NasdaqGS:TNYA

US$156.6m

Immunic

NasdaqGS:IMUX

US$139.6m

Price History & Performance

Summary of all time highs, changes and price drops for Dimerix
Historical stock prices
Current Share Price	AU$0.27
52 Week High	AU$0.27
52 Week Low	AU$0.27
Beta	0.53
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	194.44%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SBMJ.F	US Biotechs	US Market
7D	0%	-0.1%	0.8%
1Y	n/a	21.7%	33.4%

Return vs Industry: Insufficient data to determine how SBMJ.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how SBMJ.F performed against the US Market.

Price Volatility

Is SBMJ.F's price volatile compared to industry and market?
SBMJ.F volatility
SBMJ.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SBMJ.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine SBMJ.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Nina Webster	dimerix.com

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

Dimerix Limited Fundamentals Summary

How do Dimerix's earnings and revenue compare to its market cap?
SBMJ.F fundamental statistics
Market cap	US$148.09m
Earnings (TTM)	-US$11.79m
Revenue (TTM)	US$402.93k

367.5x

P/S Ratio

-12.6x

P/E Ratio

Is SBMJ.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SBMJ.F income statement (TTM)
Revenue	AU$583.48k
Cost of Revenue	AU$0
Gross Profit	AU$583.48k
Other Expenses	AU$17.66m
Earnings	-AU$17.08m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.031
Gross Margin	100.00%
Net Profit Margin	-2,926.43%
Debt/Equity Ratio	0%

How did SBMJ.F perform over the long term?

See historical performance and comparison